Pneumococcal Infections
128
6
8
105
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
52 trials with published results (41%)
Research Maturity
105 completed trials (82% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
3.1%
4 terminated out of 128 trials
96.3%
+9.8% vs benchmark
50%
64 trials in Phase 3/4
50%
52 of 105 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 105 completed trials
Clinical Trials (128)
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Extension Safety and Immunogenicity Study of GPNV-001
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
Immunization To Prevent Acute COPD Exacerbations
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels